It is a sad reality that few physicians can afford the protection ofhealth insurance for themselves, let alone for their employees. Double-digitincreases in the cost of medical insurance are driving others to severelylimit this popular fringe benefit, if not discarding it altogether. Andmatters are predicted to get worse.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.